KeyZell, a Spanish biotechnology company in the development phase of digital cancer treatments and tools, has opened a private financing round with a target of raising EUR5 million to boost its project.
The funding will be used to finance a human clinical trial with one of its innovative cancer treatments, based on Dr Nabil Hajji’s research on cellular apoptosis induced by cell receptor blockage, as well as to improve its precision medicine Artificial Intelligence system that aims to be the future of cancer medicine, thanks to an algorithm that proposes the most appropriate personalised treatment for each patient depending on the unique characteristics of each person and type of cancer.
KeyZell has already generated interest from both national private investors and North American investment funds and has successfully closed a preliminary round of EUR450,000, 50 per cent above expectations.
